ARCHIVES

Switch To NTP Holds Down Entry Of New Compounds; Obey Supports NCI On Need For More Positions

This article is from The Cancer Letter archive.

Vol. 05 No. 11 | March 16, 1979

Download PDF Visit The Full Archive

Related Articles

Blincyto Demonstrates Response In Minimal Residual Disease ALL

December 26, 2014

In Brief: O’Conor Now Top Prospect If Rauscher Leaves; Flood Gives NCI Increase Of Only $11 Million

May 14, 1976

ODAC Votes Against Cell Therapeutics Agent; Requires ChemGenex To Develop Diagnostic.

April 9, 2010

DCT Board Committee Drawing Up Plans On How To Spend Biological Response Modifiers Money

August 31, 1979

Academic Oncologists Losing Control Over Phase I Trials As For-Profits Expand

March 26, 2010

NCI Board of Scientific Advisors rejects the Institute’s $89 million proteomics research plan.

March 11, 2005